on behalf of the PRESCEN Study, Spain Arterial stiffness as assessed by carotid-femoral pulse wave velocity (cfPWV) is a marker of preclinical organ damage and a predictor of cardiovascular outcomes, independently of blood pressure (BP). However, limited evidence exists on the association between long-term variation (Δ) on aortic BP (aoBP) and ΔcfPWV. We aimed to evaluate the relationship of ΔBP with ΔcfPWV over time, as assessed by office and 24-h ambulatory peripheral BP, and aoBP. AoBP and cfPWV were evaluated in 209 hypertensive patients with either diabetes or metabolic syndrome by applanation tonometry (Sphygmocor) at baseline(b) and at 12 months of follow-up(fu). Peripheral BP was also determined by using validated oscillometric devices (office(o)-BP) and on an outpatient basis by using a validated (Spacelabs-90207) device (24-h ambulatory BP). ΔcfPWV over time was calculated as follows: ΔcfPWV = [(cfPWV fu -cfPWV b )/ cfPWV b ] × 100. ΔBP over time resulted from the same formula applied to BP values obtained with the three different measurement techniques. Correlations (Spearman 'Rho') between ΔBP and ΔcfPWV were calculated. Mean age was 62 years, 39% were female and 80% had type 2 diabetes. Baseline office brachial BP (mm Hg) was 143 ± 20/82 ± 12. Follow-up (12 months later) office brachial BP (mm Hg) was 136 ± 20/79 ± 12. ΔcfPWV correlated with ΔoSBP (Rho = 0.212; P = 0.002), Δ24-h SBP (Rho = 0.254; Po0.001), Δdaytime SBP (Rho = 0.232; P = 0.001), Δnighttime SBP (Rho = 0.320; Po0.001) and ΔaoSBP (Rho = 0.320; Po0.001). A multiple linear regression analysis included the following independent variables: ΔoSBP, Δ24-h SBP, Δdaytime SBP, Δnighttime SBP and ΔaoSBP. ΔcfPWV was independently associated with Δ24-h SBP (β-coefficient = 0.195; P = 0.012) and ΔaoSBP (β-coefficient = 0.185; P = 0.018). We conclude that changes in both 24-h SBP and aoSBP more accurately reflect changes in arterial stiffness than do office BP measurements.
INTRODUCTION
Arterial stiffness is increasingly recognized as a marker of preclinical target organ damage. 1, 2 In addition, it is credited with prognostic value as a predictor of cardiovascular events and of both cardiovascular and all-cause mortality [3] [4] [5] [6] in the general population, [7] [8] [9] as well as in patients with hypertension, 10 diabetes 11 or chronic renal disease. 12 According to most of these studies, aortic stiffness shows its prognostic value independently of blood pressure (BP) and other cardiovascular risk factors. Several methods to measure aortic stiffness have been developed, but carotid-femoral pulse wave velocity (cfPWV) remains the noninvasive 'gold standard'. 5, 13 High BP and older age are clearly related to high cfPWV, that is, aortic stiffness, and they are considered to be its main determinants.
14 Although recent studies suggest that aortic stiffness may be at least partly responsible for the development of hypertension or to contribute to its progression, [15] [16] [17] aortic stiffness has been long thought as the consequence of hypertension. Until now, most studies showing the association of BP with cfPWV were carried out by measuring peripheral BP, either office 18 or ambulatory, 19 and scarce information is reported as for the relationship between cfPWV and central BP. 20 As it has been suggested that noninvasive assessment of aortic (central) BP could relate better with preclinical target organ damage, [21] [22] [23] it may indeed be of interest to study the relationship of cfPWV with aortic BP (aoBP), in addition to the peripheral BP. Moreover, limited evidence exists on the association between long-term variation in aoBP measurements and changes in preclinical target organ damage. In addition, it is unknown whether these associations are, or not, stronger than the association between changes in office BP over time and changes in preclinical target organ damage. We hypothesize that aoBP estimation may be a better predictor of evolution of preclinical target organ damage, in terms of aortic stiffness, than peripheral BP measurements. Accordingly, we aimed to study the relationship of changes in cfPWV with the variation in BP over time, as assessed by three different methods of measurement, that is, office and 24-h ambulatory peripheral BP, as well as aoBP.
PATIENTS AND METHODS

Study population
Hypertensive subjects with impaired glucose metabolism were consecutively recruited by investigators attending specialized consults on hypertension in Spain. Hypertension was defined by at least three BP measurements taken on separate occasions with systolic (SBP) and/or diastolic (DBP) blood pressure higher than or equal to 140 mm Hg and/or 90 mm Hg, respectively, or if the patient was under antihypertensive treatment for at least 6 months. practice during the monitoring period. Baseline clinical and anthropometric features, as well as laboratory analyses, were recorded, and all patients underwent BP measurements both at baseline and at 12 months of follow-up, as detailed below. Diabetes mellitus was diagnosed if patients had a minimum of two fasting plasma glucose determinations more than 126 mg dl − 1 or when they were under antidiabetic treatment. Metabolic syndrome was diagnosed, in accordance with the consensus document then in force, 24 when the patient had two or more of the following in addition to elevated BP: abdominal obesity, as defined by a waist circumference more than 102 cm in men or more than 88 cm in women, fasting serum glucose ⩾ 100 mg dl − 1 , high-density lipoprotein plasma cholesterol 40 mg dl − 1 or less in men or 50 mg dl − 1 or less in women, plasma triglycerides 4150 mg dl − 1 or if the patient was under current treatment for any of them. Urinary albumin excretion (measured by turbidimetry in local laboratories according to current recommended standards) was determined as the average of urinary albumin/creatinine ratio from three first morning void urine samples obtained on separate days. Exclusion criteria were serious life-threatening comorbidity for the next 12 months, patients already enrolled in another clinical trial or followup clinical records not available. The study protocol conforms to the principles outlined in the Declaration of Helsinki and was approved by all correspondent research ethic committees. All participants gave written informed consent before their inclusion in the study.
BP measurement
Office brachial BP was obtained by trained personnel as the average of triplicate measurements taken at intervals of 1 min after an initial 5 min of seated rest, using validated oscillometric devices, with regular or large adult cuffs used as needed. Furthermore, after 10 min of rest in the supine position at a comfortable room temperature, aoBP was measured with the SphygmoCor device (AtCor Medical, Sydney, Australia). Mean arterial pressure was determined by mathematical integration of the radial pressure waveform obtained by applanation tonometry and calibrated using the oscillometric value of brachial SBP and DBP, as has been previously validated. 25 AoBP measurements were carried out at each investigation center by either nurses or doctors who were specifically trained to perform this technique according to current standardized recommendations. 5 They were closely monitored throughout the study to ensure accuracy in recording aoBP (details are given elsewhere). 26 Moreover, the averaged values of two consecutive valid (operator index higher than 80%) measurements at each visit were required. Intraobserver aoBP measurement coefficients of variation were 7.8% and 8.9% for SBP and DBP, respectively. The interobserver aoSBP and aoDBP coefficients of variation were 11.6% and 15.1%, respectively. Finally, 24-h ambulatory brachial BP recordings were taken with a validated device (Spacelabs-90207, Issaquah, WA, USA) at 20-minute intervals throughout both the selfreported awake and asleep periods.
All BP measurements were recorded for each included patient at baseline ( b ) and after 12 months of follow-up ( fu ).
cfPWV measurement cfPWV was evaluated by noninvasive applanation tonometry on carotid and femoral arteries (Sphygmocor device, AtCor Medical, Sydney, Australia) 27 at baseline ( b ) and after 12 months of follow-up ( fu ). The values of two valid consecutive measurements were averaged at each visit. cfPWV was computed as the distance traveled by the pulse wave divided by pulse wave transit time. Travel distance was measured to the nearest centimeter with an external tape measure over the body surface. The transit time was determined as the time difference between the feet of carotid and femoral arterial waveforms gated to ECG. cfPWV variation (Δ) over time was calculated as follows: ΔcfPWV = [(cfPWV fu − cfPWV b )/cfPWV b ] × 100. BP variation over time was calculated with the same formula applied to BP values obtained with the different measurement techniques.
Statistical analysis
A minimum number of 194 subjects were required for a bilateral contrast with an alpha risk of 0.05, a statistical power of 80% and an estimated correlation coefficient between changes in aoSBP and cfPWV of 0. 
RESULTS
A total of 209 hypertensive patients entered the study. They were 127 (61%) men and 82 (39%) women, with a mean age of 61.8 ± 11.2 years. The prevalence of type 2 diabetes mellitus was 80%, and the remaining 20% had metabolic syndrome. Dyslipidemia accounted for 69% of the patients and 13% were current smokers. At baseline, arterial stiffness (cfPWV 410 m s Table 1 and none of these characteristics showed a statistically significant change at 12 months of follow-up.
Regarding BP measurements, results on office, 24-h ambulatory BP monitoring (ABPM) and aoBP at baseline and at 12 months of follow-up are shown in Table 2 . Overall, both office BP (P o0.001 for all estimators) and aoSBP and aoDBP (P = 0.002 and P = 0.001, respectively) were significantly lower at follow-up. As regards ambulatory BP estimators, only day and night DBP, but not SBP, showed a statistically significant decrease at the 12 months of follow-up (P o 0.01 for both). Table 3 shows the correlations between ΔcfPWV and ΔBP, as assessed by brachial office BP, brachial ambulatory BP and aoBP. Changes in cfPWV at follow-up significantly correlated with variation of both SBP and DBP, as measured by office brachial BP and aoBP, as well as by brachial 24-h, daytime and nighttime ambulatory BP. The variation of pulse pressure (PP) as regards aoPP and brachial ambulatory PP, but not in terms of office brachial PP, also showed statistically significant correlations with changes in cfPWV.
A multiple linear regression analysis was performed to explore the association between the variation of the different BP parameter (s) and the variation of cfPWV over time. Variables entered into the Variation of aortic BP and arterial stiffness A Oliveras et al model were Δ in office SBP, Δ in 24-h SBP, Δ in daytime SBP, Δ in nighttime SBP and Δ in aoSBP. We applied the stepwise backward method to build the multiple regression model, in order to minimize the impact of multicollinearity. Table 4 shows the results of this analysis. As it can be observed, the independent variables that showed a statistically significant association with variation of cfPWV at 12 months of follow-up were the variation over time of 24-h SBP (β-coefficient, 0.195; P = 0.012) and the variation over time of aoSBP (β-coefficient, 0.185; P = 0.018).
DISCUSSION
The main finding of our study is that the BP measurements that better predict the variation of cfPWV over time are changes in aoSBP and 24-h SBP, but not office brachial BP changes. Accordingly, it should be reasonable to speculate that targeting a different BP estimation instead of the currently accepted office brachial BP values could be better to prevent the progression of arterial stiffness.
Although it is well known that sustained high BP favors the development and/or progression of preclinical target organ damage as measured by several markers, arterial stiffness among them, there is some evidence that treating hypertension according to office peripheral BP values does not clearly prevent from the progression of arterial stiffness. Actually, in a recent longitudinal study, therapies aimed to reduce BP in a large cohort of old men did not show to be effective in cfPWV reduction. 28 As regards peripheral ABPM, Karpettas et al. 19 showed in a small study that changes in 24-h ambulatory BP were a better predictor of changes in cfPWV than variation of office BP. This is indeed not really surprising, as ABPM has largely demonstrated a stronger association with target organ damage than office BP values. 29, 30 However, the relationship between 24-h ABPM variation overtime and changes in cfPWV or other markers of preclinical organ damage has generally been poorly documented. 19, 31 On the other hand, as regards aoBP, there is a gap in knowledge concerning the relationship between variation of aoBP and changes in preclinical target organ damage over time. To our knowledge, this is the first time that the association between aoBP changes over time and variation of cfPWV is reported. As shown, our results demonstrate that the best parameters to predict cfPWV changes at 1 year are variation of peripheral 24-h SBP and variation of aoSBP. This finding may have two important consequences. First of all, there is a BP value determined at office, that is, aoBP as measured by applanation radial artery tonometry, which is a reliable predictor of changes in arterial stiffness, at least as good as is 24-h ABPM. The main advantage is that this BP measurement is more comfortable for the patient than the 24-h ABPM, and the result is available immediately, allowing physicians to make the most appropriate therapeutic decisions right then. Second, as different antihypertensive classes have different effects on aoBP, it may be hypothesized that drugs specifically targeting aoBP could be more effective to reduce arterial stiffness, beyond the effect of these antihypertensive drugs on office BP.
The most important limitation of this study is that antihypertensive treatment was not homogeneous and could change during the observation period. However, all the patients were treated according to clinical practice along follow-up, and the number of antihypertensive drugs did not change in the observation period, which makes unlikely that the treatment is a factor that has significantly influenced these results. Another point to consider is the fact that the majority of patients evaluated in this study were diabetic. Patients with type 2 diabetes mellitus or abnormal glucose metabolism have increased arterial stiffness, even before the onset of diabetes and independently of both conventional cardiovascular risk factors and hyperglycemia or hyperinsulinemia, 32 and thus we believe that this is a target population in which assessing the influence of changes of BP over time on cfPWV would be relevant. Certainly, our results should not be extrapolated to other populations until further confirmation on Variation of aortic BP and arterial stiffness A Oliveras et al them. We must add some more possible limitations to the study. Although an accurate training and monitoring of aoBP measurement was implemented, the interobserver aoSBP and aoDBP coefficients of variation were slightly higher than expected. Finally, it is possible that a longer observational period of time could be better to reaffirm these results. Strengths of the study include a direct comparison of the three BP measurement methods (office, 24-h ABPM and aoBP) being performed in the same subjects. In addition, it is remarkable that there was no change in body mass index over time (30.9 Kg m − 2 , both baseline and at 12 months of follow-up) because there is recently published 33 evidence that weight loss may reduce cfPWV, and it could have been a confounding factor in our study.
In conclusion, we have shown that changes in both 24-h SBP and aoSBP more accurately reflect changes in arterial stiffness than do office BP measurements, in hypertensive patients with impaired glucose metabolism. It remains to be explored whether different antihypertensive drugs targeting these BP estimators would differently modify cfPWV over time. In addition, we should further evaluate whether changes in cfPWV in accordance with targeted 24-h SBP or aoSBP results in an improvement of cardiovascular risk.
What is known about the topic?
• Arterial stiffness, as measured by carotid-femoral pulse wave velocity (cfPWV), is a marker of preclinical target organ damage and a predictor of cardiovascular outcomes and mortality, independently of BP.
• Peripheral BP is reported to be associated with cfPWV.
• Limited evidence exists on the association between long-term variation in aortic (central) BP measurements and changes in preclinical target organ damage, and specifically cfPWV.
What this study adds?
• Evaluation of a cohort of patients with altered glucose metabolism shows that the BP measurements that better predict the variation of cfPWV over time are changes in both aortic and 24-h systolic BP, but not office brachial BP changes.
• This finding allows the hypothesis that different antihypertensive drugs targeting these BP estimators could differently modify cfPWV overtime.
